Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Amortizatization of Intangibles (2024 - 2026)

Evommune (EVMN) reported Amortizatization of Intangibles of $792000.0 for Q1 2026, up 86.35% year-over-year from $425000.0 in Q1 2025, and up 35.38% on a QoQ basis from $585000.0 in Q4 2025.

Evommune (EVMN) has 3 years of Amortizatization of Intangibles data on file, last reported at $792000.0 in Q1 2026.

  • Quarterly Amortizatization of Intangibles rose 86.35% year-over-year to $792000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (changed N/A YoY) and the FY2025 annual result came in at $1.8 million, down 2.8% from the prior year.
  • Amortizatization of Intangibles grew to $792000.0 in Q1 2026 per EVMN's latest filing, from $585000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $792000.0 in Q1 2026 and bottomed at $425000.0 in Q1 2025.
  • The 3-year median for Amortizatization of Intangibles is $515500.0 (2024), against an average of $562000.0.
  • The widest annual swing landed in 2025, when Amortizatization of Intangibles soared 31.17%; it then jumped 86.35% in 2026.
  • Tracing EVMN's Amortizatization of Intangibles over 3 years: stood at $446000.0 in 2024, then surged by 31.17% to $585000.0 in 2025, then surged by 35.38% to $792000.0 in 2026.
  • Per Business Quant, the three latest EVMN Amortizatization of Intangibles figures stand at $792000.0 (Q1 2026), $585000.0 (Q4 2025), and $425000.0 (Q1 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 13,267.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Evommune 744.11 Mn 532.65 Mn - 792,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 792,000.00
Mar 31, 2026 792,000.00
Dec 31, 2025 585,000.00
Dec 31, 2025 585,000.00
Mar 31, 2025 425,000.00
Mar 31, 2025 425,000.00
Dec 31, 2024 446,000.00
Dec 31, 2024 446,000.00